<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/10138">
    <title>Repository Community: null</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/10138</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/61097" />
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/61050" />
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/60915" />
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/60908" />
      </rdf:Seq>
    </items>
    <dc:date>2026-11-05T05:33:49Z</dc:date>
  </channel>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/61097">
    <title>Multi-modality image fusion model of AFM-derived extracellular vesicles for NSCLC subtype diagnosis</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/61097</link>
    <description>Title: Multi-modality image fusion model of AFM-derived extracellular vesicles for NSCLC subtype diagnosis
Author(s): Kim, Haeyoung; Park, Soohyun; Lee, Yoonhee; Ban, Jaepil; Koo, Gyogwon
Abstract: Non-small cell lung cancer (NSCLC) comprises multiple subtypes with distinct treatment strategies, making accurate subtype classification important. Therefore, this study aims to develop a multi-modality AFM-based deep learning model to improve NSCLC subtype diagnosis because extracellular vesicles (EVs) measured by atomic force microscopy (AFM) contain nanoscale biophysical information with diagnostic potential. The proposed model introduces two key components: (i) an intra-image feature extractor (IFE), which captures parameter-specific local and global dependencies, and (ii) a cross-image feature fusion module (CFFM), which mitigates domain mismatch among heterogeneous AFM parameters. Through three fusion strategies at the image, low-level feature, and high-level feature stages, the proposed model simultaneously learns intraparameter and inter-parameter relationships. The proposed model achieved an accuracy of 0.9245 and an area under the receiver operating characteristic curve (AUROC) of 0.9804, outperforming the AFM-based conventional state-of-the-art (SOTA) model by improvements of 0.1328 in accuracy and 0.0273 in AUROC. These results demonstrate that the proposed multi-modality fusion approach achieves superior diagnostic performance for AFM-based EV analysis. Furthermore, the proposed framework has the potential to be extended to AFM-based analysis of other cell types and diseases once large-scale datasets are secured. Code is released at https://github.com/sunh124/MMIF_Model_of_AFM-derived_EV.</description>
    <dc:date>2026-09-30T15:00:00Z</dc:date>
  </item>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/61050">
    <title>3차원 자기장 측정 장치 및 자기장 매핑 시스템</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/61050</link>
    <description>Title: 3차원 자기장 측정 장치 및 자기장 매핑 시스템
Author(s): 최홍수; 황준선; Ahmed Awais; Abbasi Sarmad Ahmad; 김진영</description>
  </item>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/60915">
    <title>메플로퀸 또는 이의 유도체를 포함하는 신장 질환의 치료용 조성물</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/60915</link>
    <description>Title: 메플로퀸 또는 이의 유도체를 포함하는 신장 질환의 치료용 조성물
Author(s): 이경민; 황여진
Abstract: 본 발명은 메플로퀸 (Mefloquine) 또는 이의 유도체를 포함하는 신장 질환의 치료용 조성물에 관한 것으로, 더욱 상세하게는 신장 섬유화 인자의 유전자 또는 단백질 발현 수준을 억제하는 메플로퀸에 관한 것이다.</description>
  </item>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/60908">
    <title>메틱센 또는 이의 약제학적으로 허용 가능한 염을 포함하는 신장 질환의 치료용 조성물</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/60908</link>
    <description>Title: 메틱센 또는 이의 약제학적으로 허용 가능한 염을 포함하는 신장 질환의 치료용 조성물
Author(s): 황여진; 이경민
Abstract: 본 발명의 일실시예는 메틱센 (Metixene) 또는 이의 약제학적으로 허용 가능한 염을 포함하는 신장 질환의 치료용 조성물에 관한 것으로, 더욱 상세하게는 신장 섬유화 인자의 유전자 또는 단백질 발현 수준을 억제하는 메틱센에 관한 것이다.</description>
  </item>
</rdf:RDF>

